Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 611-431-4 | CAS number: 569316-81-0
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics, other
- Type of information:
- other: Expert review and assessment
- Adequacy of study:
- key study
- Reliability:
- other: Not assignable as result is from expert assessment
- Rationale for reliability incl. deficiencies:
- other: Not assignable as result is from expert assessment
Data source
Materials and methods
- Objective of study:
- toxicokinetics
- Principles of method if other than guideline:
- Assessment of toxicokinetic behaviour of the substance derived from available data as required by REACH Annex VIII section 8.8
Test material
- Reference substance name:
- 3-((3,4-dicyanophenyl)sulfonyl)-N-(2-hydroxypropyl)propane-1-sulfonamide
- EC Number:
- 611-431-4
- Cas Number:
- 569316-81-0
- Molecular formula:
- C14H17N3O5S2
- IUPAC Name:
- 3-((3,4-dicyanophenyl)sulfonyl)-N-(2-hydroxypropyl)propane-1-sulfonamide
- Test material form:
- solid
Constituent 1
Results and discussion
Applicant's summary and conclusion
- Conclusions:
- An assessment of the potential absorption of the susbtance, based on its physico-chemical properties, suggest that absorption across the gastrointestinal mucosa is likely to be slow and part of an oral dose may be excreted in the faeces. It is possible that a proportion of the substance may be systemically absorbed following oral administration.
The susbtance is likely to be subject to metabolism via a hydroxy group on its structure and this will also aid excretion via the kidneys. Although it is possible that the substance may be systemically absorbed, there is no expectation that it will preferentially distribute to particular organs or tissues in the body. - Executive summary:
INTRODUCTION
An expert assessmentof the toxicokinetic behaviour of the test substance was undertaken using data derived from an Annex VIII testing regime.
CONCLUSION
An assessment of the potential absorption of the susbstance, based on its physico-chemical properties, suggest that absorption across the gastrointestinal mucosa is likely to be slow and part of an oral dose may be excreted in the faeces. It is possible that a proportion of the substance may be systemically absorbed following oral administration. The substance is likely to be subject to metabolism via a hydroxy group on its structure and this will also aid excretion via the kidneys. Although it is possible that the substance may be systemically absorbed, there is no expectation that it will preferentially distribute to particular organs or tissues in the body.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
